At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis
In Brief
A Phase 2 clinical trial evaluating SAR441344 IV, placebo IV, and 3 other interventions for Multiple Sclerosis. Active but no longer recruiting, targeting 129 participants across 37 sites in 10 countries.
Detailed Summary
Primary Objective: To determine the efficacy of SAR441344 as measured by reduction of the number of new active brain lesions Secondary Objective: * To evaluate efficacy of SAR441344 on disease activity as assessed by other MRI measures * To evaluate the safety and tolerability of SAR441344 * To evaluate pharmacokinetics of SAR441344
Study Details
Timeline
Interventions
Pharmaceutical form: Solution Route of administration: IV infusion
Pharmaceutical form: Solution Route of administration: IV infusion
Pharmaceutical form: Solution Route of administration: SC injection
Pharmaceutical form: Solution Route of administration: SC injection
gadolinium compound, including but not limited to Magnevist, Multihance, Prohance, or Elucirem